Preview Mode Links will not work in preview mode

Nov 15, 2011

1) Intravenous dihydroergotamine and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Pearce Korb interviews Dr. Peter Goadsby about his paper on intravenous dihydroergotamine. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Figure 4 sign. In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about myoclonic status. Over the following weeks, Dr. Burns will interview Dr. Wijdicks about imaging plus laboratory testing and take-home comments from topic discussed. The participants had nothing to disclose except Drs. Goadsby, Fugate, Burns and Wijdicks.Dr. Goadsby has served as a consultant for or served on a scientific advisory board for Advanced Bionics, Allergan, Inc., Almirall, Amgen, ATI, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Boston Scientific, CoLucid Pharmaceuticals, Coherex Medical, Inc., Eli Lilly & Company, GlaxoSmithKline, Johnson & Johnson, Medtronic, Inc., MAP Pharmaceuticals, Inc. (makers of an inhaled form of DHE; this consultation period post-dates the period of audit, the period of data collection and initial analysis), Minster Pharmaceuticals plc, Merck & Co., Inc., Neuralieve Inc., NeurAxon Inc., NeuroTherapeutics Pharma, and Pfizer Inc.; receives royalties from the publication of Mechanism and Management of Headache, 7th ed. (Elsevier, 2005); and has received research support from GlaxoSmithKline, Neuralieve Inc., Merck & Co., Inc., Johnson & Johnson, and MAP Pharmaceuticals, Inc. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.